• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Allergan proxy war gets ugly as Valeant aims to unseat the board

Allergan proxy war gets ugly as Valeant aims to unseat the board

June 2, 2014 By Arezu Sarvestani

Allergan proxy war gets ugly as Valeant aims to unseat the board

After sweetening the pot last week, activist investor Valeant Pharmaceuticals is taking a more aggressive approach in its unsolicited (and unrequited) attempt to buy Botox-maker Allergan (NYSE:AGN).

Hedge fund mogul and activist investor Bill Ackman is working with Valeant to hold a shareholder meeting to vote on a measure that would oust most Allergan’s board of directors, while Valeant is looking to take its acquisition proposal straight to shareholders.

Analysts at Sterne Agee were skeptical of the board ouster, saying that conversation with shareholders suggest that they are willing to give Allergan leadership a few months to "develop a strategy that can deliver greater shareholder value than what a merger with Valeant can offer."

"The Allergan executive team is one of the best and most shareholder-focused in the pharmaceutical industry, and our extensive experience with this team leaves us confident that management will either have a solid, value enhancing plan for Allergan or will chose to negotiate better merger terms with Valeant," Sterne Agee analyst Shibani Malhotra wrote in a note to investors today. "Investors who we have spoken with concur that it is highly unlikely that management will block a merger with Valeant simply to keep Allergan independent."

Valeant’s latest strong-arm tactics come just days after the company twice sweetened the pot as it continues to pressure Allergan leadership to accept a buyout offer now valued at $53.3 billion. Valeant is now offering $72 per share, up from the $58.50 offer made earlier last week, which was in turn an increase over the initial $48.30 bid made last month. Analysts at BMO Capital Markets called the sweetened offer a "strange and unexpected twist" in the tumultuous history of the hostile takeover attempt, adding that the new offer "substantially undervalues Allergan."

Allergan has been swatting back the acquisition pressure for weeks, saying that the company has had serious concerns with Valeant’s business model. The new bid came just days after Allergan issued a presentation questioning Valeant’s organic growth, the performance of its acquisition of Bausch & Lomb and Medicis, its ability to provide scale and the stability of its leadership team, and other issues.

Shortly after Valeant and Pershing made the offer last month, Allergan swallowed a poison pill designed to insulate it from a takeover. Days later major Allergan shareholder Polen Capital Management said the company could do better. Last month Pershing defended the bid, with Ackman urging Allergan’s board to concede to a meeting to explore the offer.

Filed Under: Cosmetic/Aesthetic, Mergers & Acquisitions, News Well, Pharmaceutical, Wall Street Beat Tagged With: Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy